Casdin Capital’s Gilead Sciences GILD Stock Holding History

Casdin Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-175,000	Closed	-$13.1M	–	43
2020 Q1	$13.1M	Buy	+175,000	New	+$12.1M	1.39%	23
2019 Q2	–	Sell	-80,000	Closed	-$5.2M	–	33
2019 Q1	$5.2M	Buy	+80,000	New	+$5.32M	0.57%	28
2018 Q1	–	Sell	-30,000	Closed	-$2.15M	–	33
2017 Q4	$2.15M	Buy	+30,000	New	+$2.28M	0.52%	24
2017 Q3	–	Sell	-75,000	Closed	-$5.31M	–	29
2017 Q2	$5.31M	Buy	+75,000	New	+$4.99M	1.96%	22
2017 Q1	–	Sell	-12,500	Closed	-$895K	–	30
2016 Q4	$895K	Buy	+12,500	New	+$929K	0.74%	25

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Casdin Capital's GILD Position: Q2 2020 in Review

Casdin Capital sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 175,000 shares — an estimated $13.1M sold.

Casdin Capital first reported a position in GILD in Q4 2016 and held it in 5 quarters. The position peaked at $13.1M in Q1 2020. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

Casdin Capital reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
Casdin Capital sold 175,000 Gilead Sciences shares in Q2 2020, an estimated $13.1M.
Casdin Capital first reported a position in Gilead Sciences in Q4 2016 and held it in 5 quarters.
Casdin Capital's Gilead Sciences position peaked at $13.1M in Q1 2020.
1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Casdin Capital's 13F filing for Q2 2020, filed 14 Aug 2020.